SFEBES2023 Poster Presentations Endocrine Cancer and Late Effects (15 abstracts)
1"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2"C.I. Parhon" National Institute of Endocrinology, Bucharest, Romania. 3"Al. Trestioreanu" Institute of Oncology, Bucharest, Romania
Background: Prevalence of neuroendocrine neoplasms is increasing and multidisciplinary approach is mandatory. This study aimed to assess the outcome of patients with gastroenteropancreatic neoplasms (GEP NEN) presenting in a tertiary endocrine center.
Methods: Retrospective study on 36 patients (16 M/20 F) with pathology confirmed GEP NEN, aged 51.9 ± 12.7 years. Serum chromogranin A, serotonin, neuron-specific enolase, NT proBNP, urinary 24h 5 hydroxyindoleacetic acid were measured. Imaging with computed tomography, magnetic resonance were used for staging and assessment of tumour size. Whole-body somatostatin receptor (SSTR) imaging was performed in a subgroup.
Results: Metastatic disease was present in 21 patients (58.3%). Median progression free survival (PFS) was 36 months, with no significant differences between different localizations. Median PFS was not reached for G1 tumors, was 26 months for G2 tumors and 3 months for G3 tumors. Median overall survival was not reached, with 86% of patients alieved at 3 years, and 80% of patients alieved at 5 years. Tumor size and serotonin levels at diagnosis were significantly higher in patients that will progress later than in patients with no further progression, P= 0.05 and 0.01 respectively.
Conclusions: initial endocrine assessment is helpful in stratifying risk in gastroenteropancreatic tumors and early diagnosis with smaller tumors improved prognosis.